Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An update from Vericel ( (VCEL) ) is now available.
Vericel Corporation announced its preliminary unaudited financial results for 2024 and provided financial guidance for 2025, revealing a 20% revenue growth for the year, with MACI and burn care products showing significant increases. The company reported a strong gross margin and profitability, highlighting a record number of MACI implants and surgeon engagements. Looking ahead, Vericel anticipates continued growth in revenue and profitability, aiming for higher gross and adjusted EBITDA margins by 2029, further solidifying its position in the advanced therapy market.
More about Vericel
Vericel Corporation is a leading provider of advanced therapies targeting the sports medicine and severe burn care markets. The company utilizes innovations in biology and medical technologies to offer a differentiated portfolio of cell therapies and specialty biologics. Vericel’s products include MACI for cartilage repair, Epicel for skin replacement in burn victims, and NexoBrid for eschar removal in burn treatments, primarily marketed in the United States.
YTD Price Performance: 8.18%
Average Trading Volume: 387,745
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.94B
For detailed information about VCEL stock, go to TipRanks’ Stock Analysis page.
